ArticleFrontiers in immunology2025
Targeting the CCL28-STAT3-PLAC8 axis to suppress metastasis and remodel tumor microenvironment in colorectal cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic inflammation plays a critical role in the initiation and progression of colorectal cancer (CRC), establishing a close link between the inflammatory microenvironment with tumor invasion and metastasis. However, the regulatory mechanisms by which inflammation-related factors promote CRC progression remain largely unclear. Methods: The biological significance of PLAC8 in colorectal cancer was investigated through clinical data analysis, mouse models of colitis-associated colorectal cancer, gene knockdown and overexpression, as well as cell migration and invasion assays. Additionally, bioinformatics analysis, activation and inhibition of PI3K/Akt and JAK/STAT3 signaling pathways, along with techniques including CUT&Tag, Western blotting, and qPCR, were employed to comprehensively analyze the detailed molecular mechanisms of PLAC8. Results: Analysis of PLAC8 expression in 78 paired clinical samples revealed significantly elevated PLAC8 expression in CRC and was identified as an independent prognostic factor. Increased expression of PLAC8 was further validated in the mouse inflammation-cancer transition model. Genetic manipulation of PLAC8 through overexpression and knockdown unequivocally established its prometastatic function in CRC, with no significant effects on proliferation, oxaliplatin resistance, or colony formation. Pharmacological modulation of AKT signaling using specific activators (SC79) and inhibitors (Capivasertib) confirmed that PLAC8 drives EMT through AKT pathway activation, resulting in increased expression of EMT-related proteins, such as N-cadherin and Snail, thereby enhancing cell migration and invasion. Further correlation analysis, CUT&Tag, and STAT3 inhibition studies revealed that CCL28 activated the STAT3 signaling pathway, promoting PLAC8 expression, and ultimately enhancing CRC invasion and metastasis. Conclusion: CCL28-mediated promotion of PLAC8 via the JAK/STAT3 signaling pathway, led to EMT in colorectal cancer cells, which played a key role in the transition from inflammation to cancer. PLAC8 served as an independent risk factor for colorectal cancer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.